To date, the following six CAR-T gene therapies have been approved only in the field of incurable blood cancer, including CD19 and B-cell maturation antigen (BCMA) targets (Mazinani & Rahbarizadeh, 2022): KymriahTM (B-cell acute lymphoblastic leukemia [ALL] and B-cell non-Hodgkin lymphoma [NHL]), YescartaTM (NHL and follicular lymphoma), TecartusTM (Mantle cell lymphoma and ALL), BreyanzyTM (NHL), AbecmaTM (multiple myeloma), and CarvykteTM (multiple myeloma). The gene discussed is TNFRSF17; the disease is plasma cell myeloma.